Camrelizumab Combined With Apatinib Mesylate
The purpose of this study is to observe the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors
Solid Tumor
DRUG: Camrelizumab combined with apatinib mesylate
AE, any adverse medical event that occurs after a subject or clinical study receives a drug or treatment regimen, up to 2 years
Objective response rate, Defined as the proportion of patients with a documented complete response, and partial response (CR+PR), up to 2 years|Disease control rate, defined as the proportion of patients with complete response, partial response and disease stabilization (CR+PR+SD), up to 2 years|Overall survival, Overall survival, up to 2 years
According to current studies, the combination of camrelizide and apatinib mesylate has significant efficacy and controllable toxicity in the treatment of solid tumors.

This study adopted camrelizumab combined with apatinib mesylate in the treatment of solid tumors, aiming to further explore the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors and provide more research data for the treatment of solid tumors.